Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

PharmaCoLogic: Preclinical Cardiac Drug Screening


技術優勢

Predictive computer based model Able to predict drug effects over multiple time and spatial scales


技術應用

Preclinical drug screening Drug rehabilitation Drug induced cardiac arrhythmias Drug interaction with inherently coexistent risk factors


詳細技術說明

Cardiotoxicity is one of the most common and dangerous risks in the development of new drugs. Due to the association between prolonged QT intervals and drug-induced proarrhythmias, QT intervals have become widely accepted as markers for cardiac arrhythmia. QT intervals, however, have become problematic as they are neither sensitive nor selective in cardiotoxicity identification. This results in the unnecessary elimination of potentially useful drugs. Researchers at the University of California, Davis have developed PharmaCoLogic: a computer based multiscale model to predict the effects of developmental drugs and drug induced cardiotoxicity. The model uses dynamic interactions of drugs and ion channels (at the atomic level) to generate kinetic function parameters. These parameters are then integrated into predictive models at the channel, cell and tissue scales, to expose fundamental arrhythmia vulnerabilities and complex emergent behaviors. The model can be used to predict inherently coexistent risk factors during preclinical drug screening and drug rehabilitation.


其他

Tech ID/UC Case

27335/2016-665-0


Related Cases

2016-665-0


國家/地區

美國

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版